Send to

Choose Destination
Genet Test Mol Biomarkers. 2011 Nov;15(11):831-4. doi: 10.1089/gtmb.2011.0027. Epub 2011 Jun 23.

Comparison of KRAS mutation tests in colorectal cancer patients.

Author information

Department of Medical Biology and Genetics, Faculty of Medicine, Istanbul Bilim University, Istanbul, Turkey.


The KRAS pathway and studies evaluating KRAS as a prognostic marker in colorectal cancer are discussed along with advances in KRAS gene mutation testing. Highly sensitive real-time polymerase chain reaction (PCR) methods were developed for this purpose. We examined the applicability of direct sequencing and two real-time PCR methods in the diagnosis of KRAS mutations. We used real-time PCR and direct sequencing-based methods to determine applicability of these KRAS mutation tests in 64 colorectal cancers. The two DNA samples found to be mutation positive by real-time PCR were analyzed again after diluting 100-fold. The results were the same. When we applied the same strategy for the direct sequencing, even a 10-fold dilution did not show the mutations. Therefore, we found that sequencing may not be informative when there are only a few mutant cells in the tumor. KRAS mutation screening on formalin-fixed, paraffin-embedded DNA is very efficient with real-time PCR methods in comparison to direct sequencing. The development and adoption of guidelines for KRAS mutation testing are crucial for success.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center